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Abstract : Quinolone resistance has been attributed to amino acid mutations in the 
type II topoisomerases of pathogens.  To better understand this mechanism of resis-
tance, we analyzed the molecular epidemiology of levooxacin-resistant Streptococcus 
pneumoniae in Japan.  We measured the quinolone susceptibility of 668 strains of S. 
pneumoniae obtained through nationwide surveillance from 2006 to 2008.  We also 
sequenced the quinolone resistance-determining regions （QRDRs） in type II topoi-
somerases and analyzed the relationship between minimum inhibitory concentration 
（MIC） and six specic mutations （Ser81 or Glu85 in GyrA, Asp435 in GyrB, Ser79 
or Asp83 in ParC, and Asp435 in ParE）.  Eighteen of the isolated strains （2.7％） 
showed intermediate susceptibility and resistance to levooxacin （MIC＞ 4 µg / ml）, 
with no signicant difference among years.  However, garenoxacin and sitaoxacin 
showed excellent activity against these strains.  Of the 18 strains, 17 （94.4％） 
showed mutation in QRDRs, while in 12 out of 14 levofloxacin-resistant strains 
（85.7％） two or more mutations were identied.  A single QRDR mutation was 
found in 3 of 60 levooxacin-susceptible strains （5％）, all of which had an MIC 
of 2 µg / ml.  We therefore found a high isolation frequency of levooxacin-resistant 
S. pneumonia in Japan over a 2-year period.  Furthermore, QRDR mutations were 
present in 5％ of susceptible strains ; these were thought to be in the early stages 
of resistance.  In the future, the increasing use of levooxacin might result in more 
strain resistance.  We therefore suggest that strong quinolones such as garenoxacin 
and sitaoxacin could be proactively administered to high-risk patients.
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Introduction
　Streptococcus pneumoniae is a gram-positive bacterial pathogen that causes respiratory and 
otolaryngological infections such as pneumonia, tympanitis and sinusitis, as well as serious 
invasive diseases, such as meningitis and septicemia.  S. pneumoniae is also a major cause of 
community-acquired pneumonia, similar to Haemophilus influenzae 1）.  Penicillin and other β- 
lactams are frequently used to treat S. pneumoniae infections ; however, the increasing number 
of penicillin intermediate-resistant S. pneumoniae （PISP） and penicillin-resistant S. pneumoniae 
（PRSP） infections that are resistant to β-lactams has become a serious clinical problem 1-3）.
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　The most effective antibiotics for community-acquired pneumonia, including PRSP, in the 
outpatient setting is a group of drugs called ‘Respiratory Quinolones’.  In Japan, tosufloxacin 
（TFLX）, levofloxacin （LVFX）, moxifloxacin （MFLX）, garenoxacin （GRNX）, and sitafloxacin 
（STFX） are included in this group.  These drugs have an excellent transfer rate to the lungs and 
show strong antibacterial activity against most community-acquired pneumonia-causing pathogens, 
including H. influenzae and Mycoplasma pneumoniae 1）.  The guidelines for community-acquired 
pneumonia in Japan recognize the effectiveness of ‘Respiratory Quinolones’ and recommend them 
for use in elderly patients or patients with underlying disease 1）.  However, quinolone-resistant S. 
pneumoniae have now been reported worldwide 4, 5）.
　Quinolone inhibits bacterial growth by disrupting the DNA replication of type II topoisomerase 6）. 
Type II topoisomerases are currently recognized to include DNA gyrase, which is responsible 
for the formation and elimination of supercoiled structures in DNA strands, and topoisomerase 
IV, which cuts and re-ligates tangled DNA during DNA replication 6）.  Each of these enzymes 
is composed of two dimers of subunit types A and B, which together form a tetramer.  DNA 
gyrase is composed of GyrA and GyrB, while topoisomerase IV comprises ParC and ParE ; 
subunit A （GyrA and ParC） possesses DNA cutting and ligating activity, and subunit B （GyrB 
and ParE） possesses ATPase activity.  Quinolones bind to the exposed double-stranded DNA 
and form a DNA—DNA gyrase-quinolone antibiotic complex, thereby preventing the re-ligation of 
DNA and subsequent replication 7）.  Amino acid substitutions in either enzyme may lead to the 
inhibition of such complex formations, and in particular, mutations in the quinolone resistance-
determining regions （QRDRs） within subunit A and B are closely related to resistance 7）. 
The mechanism of quinolone resistance by S. pneumoniae is thus attributed to mutations in 
the QRDRs and acceleration of drug efflux pumps, but high-level resistance is believed to 
solely involve mutations in the QRDRs 8）.  Previously, quinolone-resistant S. pneumoniae with 
substitutions at serine 81 and glutamic acid 85 in GyrA, at aspartic acid 435 in GyrB, at serine 
79 and aspartic acid 83 in ParC, and at aspartic acid 435 in ParE have been reported 7）.
　In this study, we investigated the frequency of LVFX-resistant S. pneumoniae in Japan and 
analyzed the six mutations in QRDRs identified in quinolone-resistant strains.  In addition, we 
performed a similar analysis of quinolone-susceptible S. pneumoniae to assess the tendency for 
quinolone resistance in Japan.
Materials and methods
Strains
　We obtained 668 S. pneumoniae strains as part of a nationwide surveillance program in Japan 
conducted from 2006 to 2008 9-11）.  S. pneumoniae identification was confirmed by detection of 
the lytA gene.  LVFX susceptibility was defined in accordance with Clinical Laboratory Standard 
Institute criteria, with an LVFX MIC ≤ 2 µg / ml defined as susceptible, 4 µg / ml as intermediate, 
and ≥8 µg / ml as resistant12）.  A total of 60 strains were examined, comprising 5 susceptible 
strains with an LVFX MIC of 0.5 µg / ml and 15 strains at 2 µg / ml extracted at random each 
year.  All strains were grown on Sheep Blood AgarⓇ （Nippon Beckton-Dickinson, Tokyo, Japan） 
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and maintained at 35℃ with 5％ CO2.  These strains were stored in a MicrobankTM system 
（IWAKI, Tokyo, Japan） at -80℃.
Susceptibility testing
　The bacterial susceptibility to antibiotics was studied by using the broth microdilution method, 
performed according to Clinical Laboratory Standards Institute guidelines 13）.  The test medium 
was prepared using cation-adjusted Mueller Hinton broth （Eikenkagaku, Tokyo, Japan） with 
lysed horse blood （Nippon Biotest Laboratory, Tokyo, Japan）.  The quinolones evaluated were 
LVFX （Daiichi Sankyo, Tokyo, Japan）, MFLX （Bayer Yakuhin, Osaka, Japan）, GRNX （Toyama 
Chemical, Toyama, Japan）, TFLX （Toyama Chemical）, and STFX （Daiichi Sankyo）.  MIC50 and 
MIC90 were calculated as the concentration to inhibit 50％ or 90％, respectively, of growth of the 
bacterial strains used.
PCR amplication and sequence analysis of QRDRs
　We determined the nucleotide sequence of lytA and the QRDRs in the gyrA, gyrB, parC, 
and parE genes.  PCR was performed in a 50-µl reaction volume containing 50 ng of DNA 
template and Phusion polymerase （FINNZYMES, Massachusetts, USA） using the GeneAmpⓇ 
PCR System 9700 （Applied Biosystems, California, USA）.  The following specific primers 
were used to obtain DNA fragments : lytA （F : 5'-TGAAGCGGATTATCACTGGC-3', R : 
5'-GCTAAACTCCCTGTATCAAGCG-3'）, gyrA （F : 5'-CCGTCGCATTCTTTACG-3', R : 
5'-AGTTGCTCCATTAACCA-3'）, gyrB （F : 5'-CATGGAAAATCCACAGATTG-3', R : 
5'-ATCGGCATCGGTCATCAAAA-3'）, parC （F : 5'-TGGGTTGAAGCCGGTTCA-3', R : 
5'-TGCTGGCAAGACCGTTGG-3'）, and parE （F : 5'-AAGGCGCGTGATGAGAGC-3', R : 
5'-TCTGCTCCAACACCCGCA-3'）14）.
　The PCR conditions were as follows : denaturation at 98℃ for 30 s and 35 amplification 
cycles of 98℃ for 5 s, annealing at 50℃ for 10 s, and polymerization at 72℃ for 15 s ; a final 
cycle of 72℃ for 5 min was used to fully extend the amplicons.
　The PCR products were purified using a GebEluteTM PCR purification Kit （SIGMA-
ALDRICH, Saint Louis, USA） and both strands of the DNA fragments were sequenced using a 
Quant-iTTM dsDNA BR Assay Kit （Invitrogen, California, USA）.  Nucleotide sequences analysis 
was commissioned from Akita Prefectural University, Biotechnology Center.
Statistical analysis
　SPSS 16.0J was used for statistical analysis.  Fisher’s exact test was used to compare the 
isolation frequency of LVFX-intermediate and -resistant S. pneumonia strains for each year.  A 
significant difference was defined by a P value below 0.05.
Results
Frequency and susceptibility of LVFX-intermediate and -resistant S. pneumoniae
　Table 1 shows the isolation frequency of LVFX-intermediate and -resistant S. pneumoniae for 
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each year.  Regarding the LVFX susceptibility assessments, 4 intermediate strains were isolated 
among a total of 668 （0.6％ ; 0 in 2006, and 2 in both 2007 and 2008）, and 14 resistant strains 
were isolated （2.1％ ; 5 in 2006, 6 in 2007, and 3 in 2008）.  Furthermore, the frequency analysis 
showed no significant difference among the years using Fisher’s exact test.  The MIC50 and 
MIC90 results for each quinolone examined are shown in Table 2, with MFLX, GRNX, and 
STFX not used in 2006, and STFX not used in 2007.  All quinolones used showed good activity 
against S. pneumonia, with a MIC50 and MIC90 for LVFX of 1 µg / ml and 2 µg / ml, respectively, 
showing a tendency to higher activity than the other quinolones.  The MIC50 and MIC90 for both 
GRNX and STFX were ＜ 0.06 µg / ml and 0.125 µg / ml, respectively, and those were the lowest 
MICs.
Quinolone susceptibilities and amino acid mutations in the QRDRs
　Table 3 shows the MIC for each quinolone and the GyrA, GyrB, ParC, and ParE amino acid 
mutations for each of the 18 LVFX-intermediate and -resistant strains.  There were four LVFX 
intermediate strains, although the other quinolones demonstrated good activity against these 
strains, and three of the four had one or more mutations in either Ser81 or Glu85 in GyrA, 
Asp435 in GyrB, Ser79 or Asp83 in ParC, and Asp435 in ParE.  However, no mutation was 
found in the 2008-236 strain.
　Of the 14 LVFX-resistant strains, 5 had an LVFX MIC of 8 µg / ml.  These 14 strains all had 
Table 1.  Annual frequency of levooxacin-intermediate and -resistant 
Streptococcus pneumoniae
LVFX MIC
（µg / ml）
2006 2007 2008 Total
Strains（％） Strains（％） Strains（％） Strains（％）
≤ 2 195（97.5） 249（96.9） 206（97.6） 650（97.3）
4 0 2（0.8） 2（1.0） 4（0.6）
≥ 8 5（2.5） 6（2.3） 3（1.4） 14（2.1）
Total 200 257 211 668
Fisher’s exact test : N.S.
Table 2.  MICs against each quinolone in all strains
Agent
2006 2007 2008 Total
MIC（µg / ml） MIC（µg / ml） MIC（µg / ml） MIC（µg / ml）
50％ 90％ 50％ 90％ 50％ 90％ 50％ 90％
LVFX 1 2 1 2 1 2 1 2
TFLX 0.125 0.25 0.25 0.25 0.125 0.25 0.125 0.25
MFLX - - 0.25 0.5 0.25 0.25 0.25 0.25
GRNX - - 0.125 0.25 ≤ 0.06 0.125 ≤ 0.06 0.125
STFX - - - - ≤ 0.06 0.125 ≤ 0.06 0.125
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at least two QRDR mutations, with three mutations in strain 2006-10, and 6 of the 14 strains 
had an LVFX MIC of 16 µg / ml.  Strains 2007-192 and 2008-45 had only a single mutation each 
（Ser79 in ParC and Ser81 in GyrA, respectively）.  Two strains had an LVFX MIC of 32 µg / ml, 
and for one it was 64 µg / ml.  Each of these had two mutations in their QRDRs.  The GRNX 
and STFX MICs were ≤ 2 µg / ml in all strains, with strong activity demonstrated against strains 
with high resistance to LVFX.
　In the analysis of LVFX MIC and amino acid mutations in each QRDR for the 60 LVFX-
susceptible strains, one strain was found in each year of the surveillance.  Strains 2006-2 （Asp83-
Val）, 2007-274 （Ser79-Tyr）, and 2008-41 （Ser79-Phe） had a mutation in ParC, and all had an 
MIC of 2 µg / ml.  No mutation in QRDRs was found among the 15 strains with an LVFX MIC 
of 0.5 µg / ml （data not shown）.
Relationship between the site of mutations in QRDRs and LVFX MIC
　The number of strains with mutations in DNAgyrase and topoisomerase IV, and their MIC 
value distribution, are shown in Fig. 1.  Among LVFX-intermediate strains （MIC＝4 µg / ml）, 
one strain was found with each of the following, respectively : only DNAgyrase mutations, only 
topoisomerase IV mutations, and mutations in both.  Only one strain had no mutation in any 
Table 3.  Quinolone susceptibilities and amino acid mutations in QRDRs of  the intermediate and resistant strains
Strain
MIC （µg/ml）＊
Amino acid changes in each QRDR
GyrA GyrB ParC ParE
LVFX TFLX MFLX GRNX STFX Ser81 Glu85 Asp435 Ser79 Asp83 Asp435
2007 26 4 1 2 0.5 0.25 Phe - - - - -
2007 229 4 1 1 0.25 0.25 Phe - - - Asn -
2008 139 4 0.25 0.5 0.125 0.25 - - - - - Asn
2008 236 4 0.5 0.25 0.25 0.5 - - - - - -
2006 10 8 2 4 2 1 Phe - - Ile Asn -
2006 42 8 8 4 0.25 0.5 Phe - - - Tyr -
2006 57 8 4 4 2 0.5 Phe - - Tyr - -
2006 114 8 1 4 0.5 0.5 Phe - - Phe - -
2006 179 8 0.5 4 0.25 0.5 Phe - - - - Asn
2007 135 16 8 4 2 1 Phe - - Phe - -
2007 192 16 ＞16 4 2 1 - - - Phe - -
2007 278 16 2 4 1 1 Tyr - - Tyr - -
2008 45 16 ＞16 4 1 0.5 Phe - - - - -
2008 165 16 ＞16 4 1 0.5 Phe - - Phe - -
2008 168 16 ＞16 4 1 0.5 Phe - - Phe - -
2007 97 32 0.125 2 0.25 0.25 - - Val Phe - -
2007 100 32 ＞16 4 1 1 Tyr - - Phe - -
2007 118 64 ＞16 8 2 2 - Lys - Tyr - -
＊MFLX : moxifloxacin, LVFX : levofloxacin, TFLX : tosufloxacin, GRNX : garenoxacin, STFX : sitafloxacin
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QRDRs.  Among 14 LVFX-resistant strains （MIC ≥ 8 µg / ml）, 12 strains （85.7％） had mutations 
in both DNAgyrase and topoisomerase IV.  As the LVFX MIC value tended to increase, the 
proportion of strains with mutations in both enzymes increased.
Discussion
　In this study, we performed an epidemiological analysis of quinolone susceptibility and a 
molecular analysis of the quinolone-resistant genes in S. pneumoniae strains clinically isolated 
in Japan.  An analysis of quinolone susceptibility showed that 2.7％ of all isolated strains 
demonstrated an increased LVFX MIC （＞4 µg / ml）.  This result was higher than previous 
reports of global surveillance by Canton et al, Sahm et al, and Morrissey et al 4, 15, 16）. 
Furthermore, no significant difference in isolation frequency was found among years, indicating 
that LVFX-resistant strains are increasing domestically.
　There was almost no change in quinolone susceptibility across the surveillance years, with 
respiratory quinolones generally showing good activity against S. pneumoniae （Table 2）.  We 
attributed the differences in antibacterial activity among the drugs to differences in inhibitory 
activity against the target enzymes.  In particular, the 50％ inhibitory concentrations （IC50） of 
GRNX and STFX against DNAgyrase and topoisomerase IV are 4-10 times lower than that of 
LVFX 17, 18）.
　Quinolone resistance was previously described to occur mechanistically via step-wise amino 
acid mutations in type II topoisomerases as follows : 1） 1st-Step mutation of either DNAgyrase 
or topoisomerase IV ; followed by 2） 2nd-Step mutation of both DNAgyrase and topoisomerase 
IV 7）.  Almost all strains with 1st-Step mutations remain susceptible, but strains with 2nd-Step 
mutations have been reported as highly resistant, since both the quinolone target enzymes, 
DNAgyrase and topoisomerase IV, are inhibited 7）.  In this study, 17 out of 18 LVFX-intermediate 
and -resistant strains （94.4％） demonstrated amino acid mutations in their QRDRs ; 12 out of 
Fig. 1.  As LVFX MIC increases, a greater proportion of strains appear 
to show mutation in both DNA Gyrase and topoisomerase IV.
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14 （85.7％） LVFX-resistant strains demonstrated 2nd-Step mutations and 2 out of 4 LVFX-
intermediate strains （2007-26 and 2008-139） showed 1st-Step mutations.  It is thought that the 
cell populations with 1st-Step mutations also contain a minority of cells with 2nd-Step mutations 
（hetero-resistance）, and that quinolone used on these cell populations could select for those cells 
with 2nd-Step mutations, thereby creating a resistant strain.  Furthermore, strains with 1st-Step 
mutations might become highly resistant if a mutation occurs newly in the other target enzyme. 
If another mutation is induced by quinolones, then they may become highly resistant 19）.
　Out of 60 LVFX-susceptible strains tested herein, we detected 3 （5％） 1st-Step strains, all 
of which showed topoisomerase IV mutations.  Similar to the above-mentioned intermediate 
strains, it is likely that high-level resistance will induce the occurrence of mutations in the other 
target enzyme, DNAgyrase.  In Japan, MIC values are not normally recorded when carrying 
out antimicrobial susceptibility tests, with only “S”, “I’’, or “R” recorded for each antibiotic. 
Therefore, even in cases for which the antimicrobial susceptibility test is recorded as ‘‘S’’, the 
administration of quinolone might lead to an increased number of resistant strains.
　In this study, 3 of the 60 LVFX-susceptible strains examined （5％） were 1st-Step strains, which 
is a significantly higher rate than previously reported, such as only 4 out of 1106 susceptible 
strains （0.4％） in a USA study 20）.  In addition, the isolation frequency of LVFX-intermediate 
and -resistant strains in this study was 2.7％, which is also higher than that reported in other 
countries4, 15, 16）.  A similar phenomenon has seen in Haemophilus influenza 21）, and these findings 
suggest that the environment in Japan is associated with a higher rate of quinolone resistance 
in comparison with other countries.  The reason for this may be the super-aging society in 
Japan.  In this study, the resistant and intermediate strains were all isolated from adults aged 
60 and over （data not shown）, and as reported previously, LVFX-resistant S. pneumoniae is 
more commonly isolated from elderly than younger patients 22）.  Since elderly people generally 
have an insufficient immunological response to pathogens in comparison to younger people, they 
tend to be administered antibiotics for longer periods.  For this reason, the selection pressure 
of antibiotics is more severe than in younger groups, setting up an environment more likely to 
favor quinolone resistance.
　Another factor may be the dose of quinolones.  Recently, the pharmacokinetics / pharmacodynamics 
（PK / PD） theory has played an important role in the administration of antibiotics.  According 
to this theory, an important parameter regarding the prevention of quinolone resistance is the 
ratio between the maximum drug concentration （CMAX） and MIC （CMAX / MIC）23）.  In Japan, 
it is becoming more common for LVFX to be administered as a single, 500-mg dose, which is 
a smaller dosage than that used in the USA （750 mg per dose）, and perhaps as a result not 
sufficient to prevent quinolone resistance.
　Ideally, studies such as ours should also consider the history of antibiotics administration 
when analyzing quinolone-resistant strains.  However, we could not investigate all the strains in 
this study in this regard.  We analyzed only the six regions considered relevant to quinolone 
resistance in domestically isolated S. pneumoniae （Ser81 or Glu85 in GyrA, Asp435 in GyrB, 
Ser79 or Asp83 in ParC, and Asp435 in ParE）.  However, one strain （2008-236） among the 
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LVFX-intermediate strains did not demonstrate any of these mutations, while two strains （2007-
192, 2008-45） among the highly resistant strains （LVFX MIC＞16 µg / ml） had mutations to 
either DNAgyrase or Topoisomerase IV.  Previously, S. pneumoniae with a similar pattern of 
mutations were reported, and this was attributed to resistance mechanisms other than that 
involving type II topoisomerase amino acid mutations 4, 24）.  QRDR mutations other than the six 
mutations investigated in this study included Lys137Asn in ParC, which was detected in 6 out 
of 60 susceptible strains （10％） and in 7 out of 18 intermediate and resistant strains （38.9％）. 
Similarly, Ile460Val in ParE was detected in 50 out of 60 susceptible strains （83.3％） and in 14 
out of 18 intermediate and resistant strains （77.8％）.  These mutations have been reported as 
not contributing to quinolone resistance, and our results supported this assumption by showing 
no relationship to the LVFX MIC25, 26）.  In this study, mutations related to quinolone resistance 
were frequently identified in QRDR regions, but we suggest that both of these other mutations, 
and the active promotion of quinolone drug efflux, may contribute to resistance.
　This study demonstrated that various factors contribute to increasing quinolone resistance in 
S. pneumoniae.  QRDR mutations were present in 5％ of even susceptible strains, which are 
thought to be in the early stages of resistance.  In the future, an increasing use of quinolones 
is likely to result in more resistant strains ; however, GRNX and STFX still demonstrate good 
activity against the quinolone-resistant S. pneumoniae strains isolated in Japan.  Our findings 
suggest that these strong quinolones should be proactively administered to elderly pneumonia 
patients and others similar patient with underlying disease.
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